Last reviewed · How we verify
Meningococcal vaccine 134612 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Meningococcal vaccine 134612 (Meningococcal vaccine 134612) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Meningococcal vaccine 134612 TARGET | Meningococcal vaccine 134612 | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Meningococcal vaccine 134612 CI watch — RSS
- Meningococcal vaccine 134612 CI watch — Atom
- Meningococcal vaccine 134612 CI watch — JSON
- Meningococcal vaccine 134612 alone — RSS
Cite this brief
Drug Landscape (2026). Meningococcal vaccine 134612 — Competitive Intelligence Brief. https://druglandscape.com/ci/meningococcal-vaccine-134612. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab